Immune Checkpoint Proteins
Among the most promising approaches to activate therapeutic antitumor immunity is the blockade of immune checkpoints. Immune checkpoint pathways involve both costimulatory and inhibitory proteins. The costimulatory receptors transduce signals to regulate T-cell activation. The inhibitory receptors regulate T-cell effector functions to prevent excessive inflammation. These agents are commonly called “immune checkpoints” because they block negative regulators of T cell immunity. Tumor cells can escape the checkpoint pathways to avoid attacks from the immune system. Therefore, disabling the immune checkpoints would help in recognizing the cells as cancerous thereby leading to an immune system assault on them.
Numerous other immune checkpoint pathways that could be the target of novel therapies have been identified and are currently under development for clinical testing. BioVision offers a comprehensive collection of proteins to support immune checkpoint blockade research.
Features & Benefits
• High Purity:: greater than 90% by SDS-PAGE and SEC-HPLC
• High Activity: validated in functional ELISA
• Low Endotoxin: less than 1EU/µ
• High Sensitivity
